Egger, KarlClemm von Hohenberg, ChristianSchocke, Michael F.Guttmann, CharlesWassermann, DemianWigand, Marlene C.Nachbauer, WolfgangKremser, ChristianSturm, BrigitteScheiber-Mojdehkar, BarbaraKubicki, MarekShenton, MarthaBoesch, Sylvia2016-09-202013Egger, Karl, Christian Clemm von Hohenberg, Michael F. Schocke, Charles R.G. Guttmann, Demian Wassermann, Marlene C. Wigand, Wolfgang Nachbauer, et al. 2013. “White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin.” Journal of Neuroimaging 24 (5) (September 9): 504–508. doi:10.1111/jon.12050.1051-2284http://nrs.harvard.edu/urn-3:HUL.InstRepos:28539565Background and Purpose—Erythropoietin (EPO) has received growing attention because of its neuro-regenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis and schizophrenia. Also in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of the present study was to assess possible therapy-associated brain white-matter changes in these patients.Methods—Nine patients with Friedreich ataxia underwent Diffusion Tensor Imaging (DTI) before and after EPO treatment. Tract-based spatial statistics (TBSS) was used for longitudinal comparison. Results—We detected widespread longitudinal increase in fractional anisotropy (FA) and axial diffusivity (D||) in cerebral hemispheres bilaterally (p<0.05, corrected), while no changes were observed within the cerebellum, medulla oblongata and pons. Conclusions—To the best of our knowledge, this is the first DTI study to investigate the effects of erythropoietin in a neurodegenerative disease. Anatomically, the diffusivity changes appear disease-unspecific, and their biological underpinnings deserve further study.en-USJournal Article2016-09-2010.1111/jon.12050